Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

A breath of not so fresh air…

João Pinto Pereira, Philippe Hantson, Thierry Pieters, Matveï Apraxine, Antoine Froidure
Breathe 2022 18: 220026; DOI: 10.1183/20734735.0026-2022
João Pinto Pereira
1Pulmonology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for João Pinto Pereira
  • For correspondence: joao.pinto@saintluc.uclouvain.be
Philippe Hantson
2Department of Intensive Care, Cliniques St-Luc, Université Catholique de Louvain, Brussels, Belgium
3Louvain Centre for Toxicology and Applied Pharmacology, Cliniques St-Luc, Université Catholique de Louvain, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philippe Hantson
Thierry Pieters
1Pulmonology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matveï Apraxine
1Pulmonology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Matveï Apraxine
Antoine Froidure
1Pulmonology Department, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
4Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antoine Froidure
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Despite being widely used as a recreational drug, “poppers” lack a legal framework for their delivery. Their composition may vary largely. This report describes a case of severe bronchiolitis following amyl nitrite mixture inhalation. https://bit.ly/3p3S7LM

A 23-year-old woman presented to the emergency department with acute onset respiratory symptoms consisting of chest discomfort, breathlessness and dry cough. She had no relevant past medical history, did not take any medication and did not smoke tobacco or cannabis.

This was her second visit to the emergency department with the same complaints. On her first visit, earlier that day, the patient had a normal physical examination and chest radiograph. Fit for discharge, the patient was sent home while waiting for her severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result.

On the second hospital admission, the patient had a normal lung auscultation contrasting with a transcutaneous oxygen saturation (SpO2) of only 91% on room air. Her respiratory rate was 20 breaths per min, her heart rate was 100 beats per min and her axillary temperature 36.0°C.

Initial work-up revealed mild inflammation (C-reactive protein (CRP) 35.3 mg·dL−1, with a normal value <5), with a leukocyte count of 6.01×103 per μL, eosinophil count of 0.37×103 per µL and D-dimer value of 431 ng·mL−1. The nasopharyngeal PCR testing for SARS-CoV-2 RNA was negative. Results of arterial blood gases analysis are displayed in (table 1).

View this table:
  • View inline
  • View popup
TABLE 1

Results of arterial blood gases

A high-resolution computed tomography (HRCT) without contrast enhancement was performed (figure 1).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Computed tomography on admission.

Task 1

Describe the chest CT in figure 1.

Answer 1

The chest CT scan revealed some nonspecific findings of multiple micronodules such as the one that can be seen in the right upper quadrant of the image; diffuse bronchial wall thickening (figure 1a), hyperinflation and the presence of endobronchial impactions.

Task 2

What is your differential diagnosis at this stage?

Answer 2

The clinical and radiological picture is compatible with an acute bronchiolitis, a nonspecific term used to describe the inflammation and the resulting airflow obstruction of small airways. The most common aetiological agents in adults are viral infections and inhalational exposure.

After further enquiry, our patient reluctantly reported a dozen inhalations of a recreational drug, commonly known as “poppers”, the night prior to her admission (figure 2).

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Isoamyl nitrite mixture sold as “leather cleaner” for legal reasons.

Pulmonary function tests (figure 3 and table 2) revealed a mixed ventilatory defect with a forced expiratory volume in the first second (FEV1) of 1 L (28% of predicted value) and a total lung capacity (TLC) of 3.61 L (68% of predicted value). Forced vital capacity was of 1.6 L (39%). Residual volume/TLC ratio was 206% of the predicted value. Obstruction was reversible following bronchodilation (administration of salbutamol 400 μg). Fractional exhaled nitric oxide (FENO) was within normal range.

FIGURE 3
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3

Spirometry and bronchodilator responsiveness testing at admission.

View this table:
  • View inline
  • View popup
TABLE 2

Pulmonary function testing at admission

The diagnosis of acute toxic bronchiolitis was established based on clinical signs, HRCT pattern and pulmonary function tests.

A bronchoscopy failed to reveal any endobronchial anomalies. Bronchoalveolar lavage composition presented a high eosinophil count (28%), along with 36% macrophages, 21% lymphocytes, 13% neutrophils and 2% epithelial cells. Endobronchial biopsies demonstrated eosinophilic infiltration in the mucosae.

Task 3

How would you treat this patient?

Answer 3

Exposure cessation is essential. Supportive care such as oxygen therapy should be provided in case of hypoxaemia. Based on a previous case series in the literature, treatment with methylprednisolone was initiated.

A short course of oral methylprednisolone (32 mg for 5 days) resulted in progressive clinical improvement. On the fifth day of her stay, our patient's clinical state had already greatly improved and the patient was discharged the next day (figure 4 and table 3).

FIGURE 4
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4

Spirometry on day 5.

View this table:
  • View inline
  • View popup
TABLE 3

Pulmonary function testing on day 5

Task 4

If a toxic origin is suspected, which substances could be responsible for respiratory effects after “poppers” use?

  • a) Isomers of amyl nitrite

  • b) Diacetyl

  • c) Derivatives of butanol

  • d) Nitrous oxide

  • e) Nitrogen dioxide

Answer 4

Correct answers: a and c. As the exact composition of “poppers” may vary, users are mainly exposed to isomers of amyl nitrite and to some organic solvents (e.g. butanol derivatives). “Poppers” may be a source of nitrous oxide and caution should be exerted with medications using this pathway.

Discussion

Bronchiolitis seldom affects adults and is most often seen in younger patients following a viral infection [1]. At older ages, viral infections remain the most common aetiology along with inhalational injuries. Although many different categorisations have been proposed [2–5], no consensual classification exists today.

The equivocal term bronchiolitis encompasses many different disease processes (table 4) [6, 7]. The timeframe is also very variable: some aetiological agents will induce an acute or chronic disease, or even both.

View this table:
  • View inline
  • View popup
TABLE 4

Disease processes encompassed by the term bronchiolitis

Usually, bronchiolitis will be responsible for dry cough and breathlessness. Other typical symptoms include chest discomfort and haemoptysis. Lung function tests will usually show non-reversible obstruction, hyperinflation and diffusing capacity of the lung for carbon monoxide (DLCO) reduction, although restrictive, mixed or reversible defects are not unusual [12]. Radiologists confronted with bronchiolitis will frequently describe features such as mosaic pattern secondary to air trapping, bronchial wall thickening, centrilobular nodules, branching linear opacities and bronchiolar dilatation [5, 13]. A lung biopsy might help obtain a definitive diagnosis, but once again, pathological findings are nonspecific and ill-defined. They usually consist of inflammatory changes such as peribronchiolar mononuclear infiltrates, fibrosis, broncho- and bronchiolectasies [14].

Concerning the clinical case described here, there is an obvious history of toxic exposure preceding hospital admission. The low blood eosinophil count along with the favourable clinical response to corticosteroids does not fit the alternative diagnosis of eosinophilic bronchiolitis. We excluded other differential diagnoses by means of serological tests, autoimmune serologies, transbronchial biopsy, cultures and respiratory panel multiplex in the bronchoalveolar lavage fluid.

One of the most infamous toxic-related bronchiolitis is an occupational condition called silo-filler's disease. First described as early as in the 1800s, it results from the inhalation of nitrogen dioxide (NO2). NO2 starts building up a few hours after the silo is filled and can reach levels of 200–2000 ppm. When in contact with water, NO2 turns into the corrosive nitrous acid. Its inhalation can result in acute, permanent and/or even life-threatening injury. Some cases of chronic exposure resulting in bronchiolitis obliterans have also been reported [5, 14–16]. NO2 toxicity has also been described in other settings such as in poorly ventilated combustion areas or indoor ice rinks [17].

Contrasting with the toxicity of inorganic nitrogen inhalation, exposure to organic derivatives appears less directly toxic for the lungs. As there is no legal framework for their delivery, the composition of “poppers” may vary largely. They belong to the family of aliphatic or cyclic alkyl nitrites. Usually, they are based on amyl, isopropyl or butyl nitrites. Although some moderate irritating effects could be observed on the eye, skin or lung, inhalation of “poppers” is almost never associated with lung toxicity, and not with bronchiolitis obliterans. Accidental aspiration of liquid amyl or butyl nitrite has caused lipoid pneumonia [18]. Methaemoglobinaemia is a possible complication of “poppers” inhalation but might be difficult to detect after a significant delay, such as in the present observation.

Also of note, another component was mentioned on the “poppers” bottle brought by the patient: 3-methyl-1-butanol (3MB), a microbial volatile organic compound (MVOC), that could be considered as a mild irritant. The fact that the patient reported no nasal or eye irritation reduces the likelihood of a 3MB toxicity [19].

Recently, outbreaks of e-cigarette or vaping use-associated lung injury (EVALI) have brought toxic inhalations back into the medical community spotlight. The umbrella term EVALI encompasses very distinct pathological and radiographic features (e.g. diffuse alveolar damage, acute eosinophilic pneumonia, lipoid pneumonia) [18, 20, 21].

As of today, no single trigger has been identified as being a sufficient condition for the occurrence of such a disorder, although some suspicion exists regarding the use of products such as vitamin E acetate, medium chain triglycerides, heavy metals and tetrahydrocannabinol [21, 22]. Criteria for the diagnosis of EVALI usually include the presence of constitutional or gastrointestinal symptoms that were absent in our clinical picture.

The scientific evidence supporting specific treatment of toxic inhalations is disappointing and at best provided by some case series. Corticosteroids seem to be the only effective treatment against nitrogen dioxide exposure with clinical, functional and radiological partial or full recovery [23, 24]. The timing and the dose of the glucocorticoid administration is not standardised although it is hypothesised that an early administration reduces the risk of further complications [24]. This beneficial effect of glucocorticoids does not seem as spectacular in other exposure-related lung diseases, such as inhalation of diacetyl seen in popcorn plant workers, textile workers suffering from Ardystil syndrome [25, 26] or inhalation of mustard gas [20]. Other therapies for inhalational bronchiolitis have been investigated such as N-acetyl cysteine, cyclophosphamide, azithromycin and bronchodilators with no strong proof of a beneficial effect.

Regardless of the aetiological agent, the severity of the inhalational injury seems dose-related, thus exposure cessation is essential. Supportive treatment should also be provided. Lung transplantation remains as a last line of treatment in cases of severe respiratory insufficiency.

After an empiric treatment by methylprednisolone, our patient presents a full recovery. No relapse occurred on follow-up.

Footnotes

  • Conflict of interest: J. Pinto Pereira has nothing to disclose.

  • Conflict of interest: P. Hantson has nothing to disclose.

  • Conflict of interest: T. Pieters has nothing to disclose.

  • Conflict of interest: M. Apraxine has nothing to disclose.

  • Conflict of interest: A. Froidure has nothing to disclose.

  • Received March 7, 2022.
  • Accepted August 3, 2022.
  • Copyright ©ERS 2022
http://creativecommons.org/licenses/by-nc/4.0/

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    1. Florin TA,
    2. Plint AC,
    3. Zorc JJ
    . Viral bronchiolitis. Lancet 2017; 389: 211–224. doi: 10.1016/S0140-6736(16)30951-5.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Myers JL,
    2. Colby TV
    . Pathologic manifestations of bronchiolitis, constrictive bronchiolitis, cryptogenic organizing pneumonia, and diffuse panbronchiolitis. Clin Chest Med 1993; 14: 611–622. doi:10.1016/S0272-5231(21)00925-4
    OpenUrlPubMed
    1. Katzenstein A-L
    . Miscellaneous II: nonspecific inflammatory and destructive diseases. In: Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease. 4th Edn. Philadelphia, Elsevier, 2006.
    1. Cagle PT,
    2. Allen TC,
    3. Beasley MB
    , eds. Diagnostic Pulmonary Pathology. 2nd Edn. New York, Informa, 2008.
  3. ↵
    1. Banks DE,
    2. Morris MJ
    . Inhalational constrictive bronchiolitis: the evolution of our understanding of this disease. Lung 2021; 199: 32–334. doi:10.1007/s00408-021-00466-2
    OpenUrl
  4. ↵
    1. Ryu JH
    . Classification and approach to bronchiolar diseases. Curr Opin Pulm Med 2006; 12: 145–151. doi:10.1097/01.mcp.0000208455.80725.2a
    OpenUrlPubMed
  5. ↵
    1. Ryu JH,
    2. Azadeh N,
    3. Samhouri B, et al.
    Recent advances in the understanding of bronchiolitis in adults. F1000Res 2020; 9: F1000. doi:10.12688/f1000research.21778.1
    OpenUrl
    1. Lai RS,
    2. Chiang AA,
    3. Wu MT, et al.
    Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Taiwan. Lancet 1996; 348: 83–85. doi: 10.1016/s0140-6736(96)00450-3
    OpenUrlCrossRefPubMed
    1. Allen TC
    . Pathology of small airways disease. Arch Pathol Lab Med 2010; 134: 702–718. doi: 10.5858/134.5.702
    OpenUrlPubMed
    1. Sun TY,
    2. Hwang G,
    3. Pancirer D, et al.
    Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour. Eur Respir J 2022; 59: 2101058. doi:10.1183/13993003.01058-2021
    OpenUrlAbstract/FREE Full Text
    1. Ryu JH,
    2. Myers JL,
    3. Swensen SJ
    . Bronchiolar disorders. Am J Respir Crit Care Med 2003; 168: 1277–1292. doi: 10.1164/rccm.200301-053SO
    OpenUrlCrossRefPubMed
  6. ↵
    1. King TE Jr.
    Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic. Semin Respir Crit Care Med 2003; 24: 567–576. doi:10.1055/s-2004-815604
    OpenUrlCrossRefPubMed
  7. ↵
    1. Winningham PJ,
    2. Martínez-Jiménez S,
    3. Rosado-de-Christenson ML, et al.
    Bronchiolitis: a practical approach for the general radiologist. Radiographics 2017; 37: 777–794. doi:10.1148/rg.2017160131
    OpenUrl
  8. ↵
    1. Visscher DW,
    2. Myers JL
    . Bronchiolitis: the pathologist's perspective. Proc Am Thorac Soc 2006; 3: 41–47. doi:10.1513/pats.200512-124JH
    OpenUrlCrossRefPubMed
    1. Ravaglia C,
    2. Poletti V
    . Bronchiolitis and bronchiolar disorders. Semin Respir Crit Care Med 2020; 41: 311–332. doi:10.1055/s-0039-3402728
    OpenUrl
  9. ↵
    1. Krefft SD,
    2. Cool CD,
    3. Rose CS
    . The emerging spectrum of exposure-related bronchiolitis. Curr Opin Allergy Clin Immunol 2018; 18: 87–95. doi:10.1097/ACI.0000000000000425
    OpenUrl
  10. ↵
    1. Brauer M,
    2. Spengler JD
    . Nitrogen dioxide exposures inside ice skating rinks. Am J Public Health 1994; 84: 429–433. doi:10.2105/ajph.84.3.429
    OpenUrlPubMed
  11. ↵
    1. Hagan IG,
    2. Burney K
    . Radiology of recreational drug abuse. Radiographics 2007; 27: 919–940. doi:10.1148/rg.274065103
    OpenUrlCrossRefPubMed
  12. ↵
    1. Ernstgård L,
    2. Norbäck D,
    3. Nordquist T, et al.
    Acute effects of exposure to vapors of 3-methyl-1-butanol in humans. Indoor Air 2013; 23: 227–235. doi:10.1111/ina.12002
    OpenUrl
  13. ↵
    1. Ghanei M,
    2. Khalili AR,
    3. Arab MJ, et al.
    Diagnostic and therapeutic value of short-term corticosteroid therapy in exacerbation of mustard gas-induced chronic bronchitis. Basic Clin Pharmacol Toxicol 2005; 97: 302–305. doi:10.1111/j.1742-7843.2005.pto_187.x
    OpenUrlCrossRefPubMed
  14. ↵
    1. Butt YM,
    2. Smith ML,
    3. Tazelaar HD, et al.
    Pathology of vaping-associated lung injury. N Engl J Med 2019; 381: 1780–1781. doi:10.1056/NEJMc1913069
    OpenUrlPubMed
  15. ↵
    1. Layden JE,
    2. Ghinai I,
    3. Pray I, et al.
    Pulmonary illness related to e-cigarette use in Illinois and Wisconsin – final report. N Engl J Med 2020; 382: 903–916. doi:10.1056/NEJMoa1911614
    OpenUrlCrossRefPubMed
  16. ↵
    1. Tse RL,
    2. Bockman AA
    . Nitrogen dioxide toxicity. Report of four cases in firemen. JAMA 1970; 212: 1341–1344. doi:10.1001/jama.1970.03170210047007
    OpenUrlCrossRefPubMed
  17. ↵
    1. Douglas WW,
    2. Hepper NG,
    3. Colby TV
    . Silo-filler's disease. Mayo Clin Proc 1989; 64: 291–304. doi:10.1016/s0025-6196(12)65249-5
    OpenUrlPubMed
  18. ↵
    1. Akpinar-Elci M,
    2. Travis WD,
    3. Lynch DA, et al.
    Bronchiolitis obliterans syndrome in popcorn production plant workers. Eur Respir J 2004; 24: 298–302. doi:10.1183/09031936.04.00013903
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Romero S,
    2. Hernández L,
    3. Gil J, et al.
    Organizing pneumonia in textile printing workers: a clinical description. Eur Respir J 1998; 11: 265–271. doi:10.1183/09031936.98.11020265
    OpenUrlAbstract
PreviousNext
Back to top
Vol 18 Issue 3 Table of Contents
Breathe: 18 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A breath of not so fresh air…
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
A breath of not so fresh air…
João Pinto Pereira, Philippe Hantson, Thierry Pieters, Matveï Apraxine, Antoine Froidure
Breathe Sep 2022, 18 (3) 220026; DOI: 10.1183/20734735.0026-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
A breath of not so fresh air…
João Pinto Pereira, Philippe Hantson, Thierry Pieters, Matveï Apraxine, Antoine Froidure
Breathe Sep 2022, 18 (3) 220026; DOI: 10.1183/20734735.0026-2022
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory clinical practice
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • An unusual progressive stridor
  • A difficult pleural effusion in a cirrhotic patient
Show more Case reports

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society